Your browser doesn't support javascript.
loading
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.
Bayes, Adam; Short, Brooke; Zarate, Carlos A; Park, Lawrence; Murrough, James W; McLoughlin, Declan M; Riva-Posse, Patricio; Schoevers, Robert; Veraart, Jolien; Parikh, Sagar; Glue, Paul; Fam, Johnson; McShane, Rupert; Galvez, Veronica; Martin, Donel; Tor, Phern-Chern; Brunoni, Andre R; Loo, Colleen K.
Afiliação
  • Bayes A; Black Dog Institute, UNSW Sydney, Australia; School of Psychiatry, UNSW Sydney, Australia. Electronic address: a.bayes@unsw.edu.au.
  • Short B; St Vincent's Hospital, Sydney, Australia.
  • Zarate CA; Division of Intramural Research Program, National Institute of Mental Health, MD, United States.
  • Park L; Division of Intramural Research Program, National Institute of Mental Health, MD, United States.
  • Murrough JW; Depression and Anxiety Centre for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • McLoughlin DM; Department of Psychiatry, Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland.
  • Riva-Posse P; Department of Psychiatry and Behavioral Sciences at Emory University, Atlanta, GA, United States.
  • Schoevers R; The University Medical Center Groningen, Groningen, the Netherlands.
  • Veraart J; The University Medical Center Groningen, Groningen, the Netherlands.
  • Parikh S; Department of Psychiatry, University of Michigan, MI, United States.
  • Glue P; University of Otago, Dunedin, New Zealand.
  • Fam J; Department of Psychological Medicine, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • McShane R; Department of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • Galvez V; Corporacio Sanitaria Parc Tauli, Universitat Autonoma de Barcelona, I3PT, Institut d'Investigacio i Innovacio Parc Tauli, Sabadell, Barcelona, Spain.
  • Martin D; Black Dog Institute, UNSW Sydney, Australia.
  • Tor PC; Institute of Mental Health, Singapore.
  • Brunoni AR; Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da USP, Brazil.
  • Loo CK; Black Dog Institute, UNSW Sydney, Australia; School of Psychiatry, UNSW Sydney, Australia.
J Affect Disord ; 308: 44-46, 2022 07 01.
Article em En | MEDLINE | ID: mdl-35405177
ABSTRACT

OBJECTIVES:

On a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice.

METHODS:

An international group of psychiatrists discussed the issue of safety of ketamine and esketamine and came to a consensus on key safety gaps.

RESULTS:

There is no standard safety monitoring for off-label generic ketamine. For intranasal esketamine, each jurisdiction providing regulatory approval may specify monitoring. Treatment is often provided beyond the period for which safety has been demonstrated, with no agreed framework for monitoring of longer term side effects for either generic ketamine or intranasal esketamine.

LIMITATIONS:

The KSET has established face and content validity, however it has not been validated against other measures of safety.

CONCLUSIONS:

We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psiquiatria / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Transtorno Depressivo Resistente a Tratamento / Ketamina Limite: Humans Idioma: En Revista: J Affect Disord Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psiquiatria / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Transtorno Depressivo Resistente a Tratamento / Ketamina Limite: Humans Idioma: En Revista: J Affect Disord Ano de publicação: 2022 Tipo de documento: Article